课题基金 / 基金详情

Cytokine, chemokine and antiangiogenic gene therapy for murine renal cell carcinoma

Cytokine, chemokine and antiangiogenic gene therapy for murine renal cell carcinoma
细胞因子、趋化因子和抗血管生成基因治疗小鼠肾细胞癌
批准号:
12671536
负责人:
KANAYAMA Hiro-omi
金额:
$1.28万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2000
资助国家:
日本
项目状态:
已结题
起止时间:
2000 至 2001

项目摘要

项目成果

KANAYAMA Hiro-omi的其他基金

相似基金

相关文献

中文摘要
翻译
附加淋巴趋动素基因治疗增强IL-12基因治疗的抗肿瘤免疫。我们研究了IL-12和淋巴趋化素表达质粒联合基因治疗。在BALB/c小鼠腹腔皮内接种同种小鼠肾癌细胞(Renca)。虽然随后使用基因枪注射IL-12和淋巴趋化素表达质粒,但没有协同作用。白细胞介素12表达质粒体内转移的癌症疫苗治疗。研究了辐照癌细胞皮内接种与基因枪转染IL-12基因联合治疗的方法。这种联合治疗通过增强CTL和CD4^+和CD8^+T细胞对肿瘤的浸润来抑制肿瘤在远处的建立。血管抑制素cDNA在小鼠肾细胞癌体内表达对肿瘤生长的抑制作用。构建血管抑制素表达质粒,通过脂质体转染Renca细胞。选择这些转染的细胞并扩增。Western免疫印迹法证实血管抑制素的表达。我们发现转染血管抑制素的细胞通过抗血管生成作用抑制亲本Renca在远处同时植入的生长。基因枪联合IL-12和血管抑制素基因治疗无增效作用。
英文摘要
Enhancement of antitumor immunity of IL-12 gene therapy by additional lymphotactin gene therapy. We studied combination gene therapy with IL-12 and lymphotactin expression plasmid. BALB/c mice were inoculated with syngeneic murine renal cancer cells (Renca) intradermally in the abdomen. Although this was followed by an injection of IL-12 and lymphotactin expression plasmid using the gene gun, there was no synergistic effect.A cancer vaccine therapy with in vivo transfer of interleukin 12 expression plasmid. We studied combination treatment with intradermal inoculatioiKof irradiated cancer cells and transfectipn with IL-12 gene using gene gun. This combination treatment inhibited tumor establishment at a distant site with enhancement of CTL and tumor infiltration by CD4^+ and CD8^+T cells.Suppression of tumor growth by expression of angiostatin cDNA in a murine renal cell carcinoma in vivo. Angiostatin expression plasmid was constructed and introduced into Renca cells by lipofection. These transfected cells were selected and expanded. Expression of angiostatin was confirmed by Western immunoblotting. We showed that implantation of angiostatin-transfected cells inhibited the growth of parental Renca implanted simultaneously at a distant site via antiangiogenic effect. There was no synergistic effect in the combination therapy with IL-12 and angiostatin gene using gene gun.
期刊论文(7)
专著(0)
科研奖励(0)
会议论文
MASA-AKI NISHITANI: "Gtokine gene therapy for cancer with naked DNA"MOLECULAR UROLOGY. 4・2. 47-50 (2000)
MASA-AKI NISHITANI:“用裸DNA治疗癌症的Gtokine基因疗法”分子泌尿学4·2(2000)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Fukumori T: "Expression of Angiostatin cDNA in a Murine Renal Cell Carcinoma Suppresses Tumor Growth in Vivo"Urology. (in press).
Fukumori T:“血管抑制素 cDNA 在鼠肾细胞癌中的表达抑制体内肿瘤生长”泌尿学。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Nishitani M: "A convenient cancer vaccine therapy with in vivo transfer of Interleukin 12 expression plasmid using gene gun technology after priming with irradiated carcinoma cells"Cancer Gene Therapy. 9. 156-163 (2002)
Nishitani M:“一种方便的癌症疫苗疗法,在用受辐射的癌细胞引发后,使用基因枪技术体内转移白细胞介素 12 表达质粒”癌症基因疗法。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Fukumori T.: "Expression of Angiostatin cDNA in a Murine Renal Cell Carcinoma Suppresses Tumor Growth in Vivo"Urology. (in press).
Fukumori T.:“血管抑制素 cDNA 在鼠肾细胞癌中的表达抑制体内肿瘤生长”泌尿学。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
The interaction of cancer cell and stromal cell in urinary cancer-The approach of stromal therapy-
  • 批准号:
    21390442
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
  • 资助金额:
    $11.73万
  • 财政年份:
    2009
  • 负责人:
    KANAYAMA Hiro-omi
  • 依托单位:
The role of galectin-3 in human renal cell cancer cells
  • 批准号:
    16591599
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 资助金额:
    $1.79万
  • 财政年份:
    2004
  • 负责人:
    KANAYAMA Hiro-omi
  • 依托单位:
The roles IGF of family in renal cell carcinoma
  • 批准号:
    14571501
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 资助金额:
    $1.66万
  • 财政年份:
    2002
  • 负责人:
    KANAYAMA Hiro-omi
  • 依托单位:
Molecular Biological Analysis of function and signal transduction of renin-binding protein
  • 批准号:
    09671631
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 资助金额:
    $0.77万
  • 财政年份:
    1997
  • 负责人:
    KANAYAMA Hiro-omi
  • 依托单位:
海外基金